NRXPNRX Pharmaceuticals, Inc.同业对比
NRX Pharmaceuticals, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRXP本股 | $145M#9 | — | — | 118.6x#4 | — | -13.9%#7 | -1324.4%#4 | — | — | — | — | — |
| ORMP | $192M#2 | 1.1x#1 | 1.0x#3 | 96.1x#3 | — | 573.1%#2 | -754.4%#3 | 0.0%#2 | -4.4%#3 | — | 97.9%#2 | — |
| ORGO | $180M#3 | — | 1.2x#5 | 0.3x#1 | 17.0%#1 | 4011.1%#1 | 7.9%#1 | 25.0%#1 | 23.2%#1 | — | -71.3%#6 | — |
| NERV | $167M#4 | — | — | — | — | -20492.7%#13 | — | — | — | — | — | — |
| RNA | $163M#5 | — | 0.8x#2 | — | — | — | — | 0.0%#3 | — | — | -77.1%#7 | — |
| CNTN | $162M#6 | — | 0.4x#1 | — | — | -194.5%#10 | — | -7.9%#4 | — | — | — | — |
| LFCR | $158M#7 | — | — | 1.2x#2 | 0.5%#2 | -422.5%#11 | -13.4%#2 | — | -28.7%#4 | 3#1 | -47.4%#5 | — |
| SPRB | $156M#8 | — | 1.9x#7 | — | -100.0%#4 | 26.5%#5 | — | -46.5%#5 | — | — | 536.0%#1 | — |
| CRBP | $140M#10 | — | 1.4x#6 | — | -100.0%#4 | -95.3%#9 | — | -76.8%#8 | -93.1%#5 | — | -29.9%#4 | — |
| IMUX | $138M#11 | 5.0x#2 | 1.1x#4 | — | — | 3.3%#6 | — | -76.2%#7 | — | — | 23.9%#3 | — |
| CURX | $135M#12 | — | 28.2x#11 | — | — | -1068.8%#12 | — | -88.2%#9 | — | — | — | — |
| UNCY | $133M#13 | — | 2.5x#8 | 196.8x#5 | -29.0%#3 | 27.7%#4 | -4372.9%#5 | -49.8%#6 | — | — | — | — |
| APMD | $1.1B#1 | — | — | — | — | — | — | — | — | — | — | — |
| HURA | $129M#14 | — | 7.0x#9 | — | — | -34.8%#8 | — | -167.6%#10 | -0.1%#2 | — | — | — |
| BMEA | $126M#15 | — | 10.4x#10 | — | — | 55.4%#3 | — | -509.2%#11 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议